Company Profile
Cartesian Therapeutics Stock Price, News & Analysis
- Ticker:
- RNAC
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Cartesian Therapeutics sits inside the cell therapy universe where trial execution and regulatory timing can change the investment case quickly.
Stock performance
10.18 USD (+2.31%)
Close
Last updated: June 23, 2026 at 00:00
299.1M USD
Market cap
Why the stock is moving
RNAC is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Cartesian Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cartesian Therapeutics sits inside the cell therapy universe where trial execution and regulatory timing can change the investment case quickly.
Business Model Characteristics
Cartesian Therapeutics follows a platform-led model where readouts, manufacturing progress, and commercialization milestones matter as much as the initial science. The market tends to reprice the stock quickly whenever adoption, safety, or label-expansion signals improve.
Position Within the Biotechnology Landscape
Compared with larger diversified biotech peers, Cartesian Therapeutics sits at the high-catalyst end of the landscape, where cell therapy names can move sharply on data, approvals, and launch milestones.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Cartesian Therapeutics (RNAC)?
Cartesian Therapeutics (RNAC) most recently closed at 10.18 USD, a +2.31% move versus the previous session.
What is the market cap of Cartesian Therapeutics (RNAC)?
Cartesian Therapeutics currently has a market capitalization of 299.1M USD on BioPharmSignal.
What does Cartesian Therapeutics do?
Cartesian Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
On which exchange is RNAC stock listed?
Cartesian Therapeutics (RNAC) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Cartesian Therapeutics sits inside the cell therapy universe where trial execution and regulatory timing can change the investment case quickly., Biotechnology.
What is Cartesian?
Cartesian Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases.
Which conditions is Cartesian Therapeutics targeting with Cartesian?
Cartesian Therapeutics is associated with oncology based on its company overview and current catalyst commentary.
What is Therapeutics?
Cartesian Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases.
What is Investors?
Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.